Long-term toxicity and survival outcomes after stereotactic ablative radiotherapy for patients with centrally located thoracic tumors
- Atalar Banu
- Mustafayev Teuta Zoto
- Sio Terence T.
- Sahin Bilgehan
- Gungor Gorkem
- Aydın Gokhan
- Yapici Bulent
- Ozyar Enis
Publication date
June 2020
DOI Publisher
Walter de Gruyter GmbH Journal
Radiology and OncologyAbstract
Stereotactic ablative radiotherapy (SABR) is effective for thoracic cancer and metastases; however, adverse effects are greater for central tumors. We evaluated factors affecting outcomes and toxicities after SABR for patients with primary lung and oligometastatic tumors
Add to ORKG